Not available outside of the UK & Ireland.
Application
SB 657510 may be used to study the urotensin II receptor-mediated signaling.
Biochem/physiol Actions
SB 657510 slows development of diabetes-associated atherosclerosis in mouse model of diabetes.1
SB-657510 is a selective urotensin-II (UT) receptor antagonist. Human urotensin-II (hU-II) is proposed to play a significant role in cardiorenal and metabolic disease states, including heart failure, atherosclerosis, hypertension.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Packaging
5, 25 mg in glass bottle
This product has met the following criteria to qualify for the following awards: